Compare Stocks: CTNM, HCM, GHRS, and CMPS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMPS Compass Pathways	$13.45 +1.2%	$12.63	$3.97 ▼ $15.40	$1.79B	2.5	3.26 million shs	1.35 million shs
CTNM Contineum Therapeutics	$14.19 -7.3%	$14.07	$7.20 ▼ $16.91	$575.60M	0.74	344,041 shs	747,306 shs
GHRS GH Research	$29.49 +4.6%	$26.25	$11.83 ▼ $31.44	$1.93B	1.29	351,913 shs	233,831 shs
HCM HUTCHMED	$12.20 +0.3%	$11.13	$9.77 ▼ $18.30	$2.12B	0.23	45,276 shs	13,090 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMPS Compass Pathways	+1.20%	-0.66%	+1.05%	+29.70%	+213.52%
CTNM Contineum Therapeutics	-7.25%	-5.65%	-3.01%	+3.43%	+104.17%
GHRS GH Research	+4.61%	-2.58%	+9.55%	+37.87%	+134.79%
HCM HUTCHMED	+0.33%	-2.48%	+5.26%	-2.48%	-23.75%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMPS Compass Pathways	$13.45 +1.2%	$12.63	$3.97 ▼ $15.40	$1.79B	2.5	3.26 million shs	1.35 million shs
CTNM Contineum Therapeutics	$14.19 -7.3%	$14.07	$7.20 ▼ $16.91	$575.60M	0.74	344,041 shs	747,306 shs
GHRS GH Research	$29.49 +4.6%	$26.25	$11.83 ▼ $31.44	$1.93B	1.29	351,913 shs	233,831 shs
HCM HUTCHMED	$12.20 +0.3%	$11.13	$9.77 ▼ $18.30	$2.12B	0.23	45,276 shs	13,090 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMPS Compass Pathways	+1.20%	-0.66%	+1.05%	+29.70%	+213.52%
CTNM Contineum Therapeutics	-7.25%	-5.65%	-3.01%	+3.43%	+104.17%
GHRS GH Research	+4.61%	-2.58%	+9.55%	+37.87%	+134.79%
HCM HUTCHMED	+0.33%	-2.48%	+5.26%	-2.48%	-23.75%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CMPS Compass Pathways	2.88	Moderate Buy	$23.36	73.66% Upside
CTNM Contineum Therapeutics	2.40	Hold	$20.25	42.71% Upside
GHRS GH Research	2.67	Moderate Buy	$45.00	52.59% Upside
HCM HUTCHMED	2.17	Hold	$14.87	21.86% Upside

Current Analyst Ratings Breakdown

Latest CTNM, HCM, GHRS, and CMPS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/10/2026	GHRS GH Research	New Street Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$65.00
8/10/2026	GHRS GH Research	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/7/2026	GHRS GH Research	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$34.00 ➝ $40.00
8/7/2026	CMPS Compass Pathways	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$70.00 ➝ $65.00
8/7/2026	GHRS GH Research	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$35.00 ➝ $40.00
8/6/2026	CMPS Compass Pathways	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$17.00 ➝ $18.00
8/6/2026	CMPS Compass Pathways	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$22.00 ➝ $21.00
8/6/2026	CMPS Compass Pathways	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$17.00 ➝ $22.00
8/6/2026	GHRS GH Research	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$32.00 ➝ $39.00
8/5/2026	CMPS Compass Pathways	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
7/31/2026	HCM HUTCHMED	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D)

(Data available from 8/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CMPS Compass Pathways	N/A	N/A	N/A	N/A	$0.63 per share	N/A
CTNM Contineum Therapeutics	$50M	10.68	N/A	N/A	$6.37 per share	2.23
GHRS GH Research	N/A	N/A	N/A	N/A	$5.24 per share	N/A
HCM HUTCHMED	$548.51M	3.88	$2.71 per share	4.51	$7.31 per share	1.67

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CMPS Compass Pathways	-$287.86M	-$4.62	N/A	N/A	N/A	N/A	-49.63%	-13.08%	11/3/2026 (Estimated)
CTNM Contineum Therapeutics	-$59.98M	-$1.73	N/A	N/A	N/A	N/A	-24.73%	-23.51%	10/29/2026 (Estimated)
GHRS GH Research	-$48.26M	-$1.00	N/A	N/A	N/A	N/A	-20.07%	-19.41%	N/A
HCM HUTCHMED	$456.91M	N/A	N/A	55.45	N/A	N/A	N/A	N/A	N/A

Latest CTNM, HCM, GHRS, and CMPS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	GHRS GH Research	-$0.2860	-$0.23	+$0.0560	-$0.23	N/A	N/A
8/5/2026	Q2 2026	CMPS Compass Pathways	-$0.3881	-$1.88	-$1.4919	-$1.88	N/A	N/A
7/30/2026	Q2 2026	CTNM Contineum Therapeutics	-$0.4488	-$0.40	+$0.0488	-$0.40	N/A	N/A
7/30/2026	H1 2026	HCM HUTCHMED	$0.1450	$0.05	-$0.0950	$0.05	$304.16 million	$139.14 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CMPS Compass Pathways	N/A	N/A	N/A	N/A	N/A
CTNM Contineum Therapeutics	N/A	N/A	N/A	N/A	N/A
GHRS GH Research	N/A	N/A	N/A	N/A	N/A
HCM HUTCHMED	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CMPS Compass Pathways	0.60	1.30	1.30
CTNM Contineum Therapeutics	N/A	37.17	37.17
GHRS GH Research	N/A	28.70	28.70
HCM HUTCHMED	0.06	5.64	5.50

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CMPS Compass Pathways	46.19%
CTNM Contineum Therapeutics	N/A
GHRS GH Research	56.90%
HCM HUTCHMED	8.82%

Insider Ownership

Company	Insider Ownership
CMPS Compass Pathways	2.82%
CTNM Contineum Therapeutics	7.90%
GHRS GH Research	41.60%
HCM HUTCHMED	3.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CMPS Compass Pathways	120	134.95 million	131.14 million	Optionable
CTNM Contineum Therapeutics	31	37.62 million	34.65 million	N/A
GHRS GH Research	10	68.61 million	40.07 million	Optionable
HCM HUTCHMED	1,796	174.47 million	168.19 million	Not Optionable

CTNM, HCM, GHRS, and CMPS Headlines

Recent News About These Companies

HUTCHMED (NASDAQ:HCM) Upgraded by Wall Street Zen to "Buy" Rating

August 8, 2026 | americanbankingnews.com

HUTCHMED (NASDAQ:HCM) Stock Rating Upgraded by Wall Street Zen

August 8, 2026 | marketbeat.com

HUTCHMED (NASDAQ:HCM) Share Price Crosses Above 50 Day Moving Average - Here's Why

August 7, 2026 | marketbeat.com

HUTCHMED (NASDAQ:HCM) Announces Earnings Results

July 31, 2026 | marketbeat.com

HUTCHMED Reports 2026 Interim Results

July 31, 2026 | tmcnet.com

HUTCHMED (China) Limited (HCM) Q2 2026 Earnings Call Transcript

July 30, 2026 | seekingalpha.com

HUTCHMED H1 Earnings Call Highlights

July 30, 2026 | marketbeat.com

HUTCHMED (China) Limited 2026 Q2 - Results - Earnings Call Presentation

July 30, 2026 | seekingalpha.com

Hutchmed China Ltd. Reveals Fall In H1 Income

July 30, 2026 | finanznachrichten.de

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Average Rating of "Hold" from Brokerages

July 30, 2026 | marketbeat.com

HUTCHMED (HCM) Projected to Release Earnings on Thursday

July 23, 2026 | marketbeat.com

Hutchmed: Bullish On Their Commercial Prospects And Pipeline Catalysts

July 19, 2026 | seekingalpha.com

HUTCHMED (NASDAQ:HCM) Stock Price Down 6% - Here's Why

July 17, 2026 | marketbeat.com

HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification

July 2, 2026 | globenewswire.com

HUTCHMED to Announce 2026 Half-Year Financial Results

June 30, 2026 | globenewswire.com

HUTCHMED's experimental drug shows durable responses in advanced bile duct cancer trial

June 25, 2026 | msn.com

Syndio Acquires Embrace.ai

June 23, 2026 | businesswire.com

isolved Introduces Autonomous AI Agents Built to Own HR Outcomes â€” Brings Unified HCM Platform to Anthropic's Claude Connectors Directory

June 16, 2026 | globenewswire.com

Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)

June 16, 2026 | prnewswire.com

isolved Honors Top-Performing Partners at Annual Connect for Partners Event

June 15, 2026 | globenewswire.com

isolved Introduces New Strategic Marketplace Partners at Connect 2026, Extending People Cloud™ Capabilities for Employers and Employees

June 15, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTNM, HCM, GHRS, and CMPS Company Descriptions

Compass Pathways NASDAQ:CMPS

$13.45 +0.16 (+1.20%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$13.48 +0.03 (+0.19%)

As of 08/14/2026 07:57 PM Eastern

Compass Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to Compass Pathways plc in August 2020. Compass Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Contineum Therapeutics NASDAQ:CTNM

$14.19 -1.11 (-7.25%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$14.15 -0.04 (-0.28%)

As of 08/14/2026 07:34 PM Eastern

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

GH Research NASDAQ:GHRS

$29.49 +1.30 (+4.61%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$29.82 +0.33 (+1.10%)

As of 08/14/2026 07:38 PM Eastern

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

HUTCHMED NASDAQ:HCM

$12.20 +0.04 (+0.33%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$12.21 +0.01 (+0.08%)

As of 08/14/2026 07:34 PM Eastern

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CTNM, HCM, GHRS, and CMPS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CTNM, HCM, GHRS, and CMPS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CTNM, HCM, GHRS, and CMPS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTNM, HCM, GHRS, and CMPS Company Descriptions

Compass Pathways NASDAQ:CMPS

Contineum Therapeutics NASDAQ:CTNM

GH Research NASDAQ:GHRS

HUTCHMED NASDAQ:HCM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CTNM, HCM, GHRS, and CMPS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CTNM, HCM, GHRS, and CMPS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CTNM, HCM, GHRS, and CMPS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTNM, HCM, GHRS, and CMPS Company Descriptions

Compass Pathways NASDAQ:CMPS

Contineum Therapeutics NASDAQ:CTNM

GH Research NASDAQ:GHRS

HUTCHMED NASDAQ:HCM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools